RT Journal Article
SR Electronic
T1 A new transmission route for the propagation of the SARS-CoV-2 coronavirus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.14.20022939
DO 10.1101/2020.02.14.20022939
A1 Antoine Danchin
A1 Patrick Tuen Wai Ng
A1 Gabriel Turinici
YR 2020
UL http://medrxiv.org/content/early/2020/02/18/2020.02.14.20022939.abstract
AB Background A novel coronavirus (SARS-CoV-2) spread from the capital of the Hubei province in China to the rest of the country, then to most of the world. To anticipate future trends in the development of the epidemic, we explore here, based on public records of infected persons how variation in the virus tropism could end up in different patterns, warranting specific way to handle the epidemic.Methods We use a compartmental model to describe the evolution of an individual through several possible states: susceptible, infected, alternative infection, detected and removed. We fit the parameters of the model to the existing data taking into account significant quarantine changes where necessary.Results The model indicates that Wuhan quarantine measures were effective but that alternative virus forms and a second propagation route are compatible with available data. For Singapore and Shenzhen region the secondary route does not seem to be active yet and the epidemic size limited.Conclusions The alternative infection tropism (the gut tropism) and a secondary propagation route are validated hypotheses using a model fitted by the available data. Corresponding prevention measures that take into account both routes should be implemented to the benefit of epidemic control.Competing Interest StatementAD is employed by Stellate Therapeutics (fka Amabiotics), a company that works on treatment of neurodegenerative diseases.Funding StatementAuthors were funded by their respective employers.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesno personal of private data were used in this work.